tiprankstipranks
Trending News
More News >
Chaoju Eye Care Holdings Ltd. (HK:2219)
:2219
Hong Kong Market

Chaoju Eye Care Holdings Ltd. (2219) AI Stock Analysis

Compare
1 Followers

Top Page

HK:2219

Chaoju Eye Care Holdings Ltd.

(2219)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 5.2)
Rating:68Neutral
Price Target:
HK$3.00
â–²(10.70% Upside)
Chaoju Eye Care Holdings Ltd. has a solid financial foundation and attractive valuation, which are significant strengths. However, the technical analysis indicates bearish momentum, which is a concern. The absence of earnings call insights and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong demand for services and effective market positioning, supporting long-term business expansion.
Cash Flow Management
Strong cash flow management enhances liquidity and provides financial flexibility for strategic investments and operational stability.
Balance Sheet Health
A low debt-to-equity ratio indicates financial stability and reduces risk, allowing for sustainable growth and resilience against economic fluctuations.
Negative Factors
Net Profit Margin Decline
A declining net profit margin may signal cost pressures or inefficiencies, potentially impacting profitability and requiring strategic cost management.
Decreased Return on Equity
A decrease in return on equity suggests reduced profitability relative to shareholder equity, which may affect investor confidence and capital efficiency.
Earnings Volatility
Significant earnings volatility can create uncertainty in financial performance, potentially affecting strategic planning and investor perception.

Chaoju Eye Care Holdings Ltd. (2219) vs. iShares MSCI Hong Kong ETF (EWH)

Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model

Company DescriptionChaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia control, as well as optical products and services. The company also provides basic ophthalmic services, including cataract, glaucoma, ocular fundus diseases, ocular muscle diseases, refraction errors, pediatric ophthalmology, ocular surface diseases, lacrimal diseases, orbital diseases, oculoplastic, and ocular trauma. As of December 31, 2021, it operated a network of 17 ophthalmic hospitals, 24 optical centers, and 2 clinics in Zhejiang, Jiangsu, Shanxi, and Hebei provinces, as well as in Inner Mongolia. The company was founded in 1988 and is headquartered in Beijing, China.
How the Company Makes MoneyChaoju Eye Care Holdings Ltd. generates revenue through multiple streams, primarily from the sale of its core products such as intraocular lenses and surgical instruments used in eye care procedures. The company benefits from a growing demand for ophthalmic surgeries due to an increasing prevalence of eye-related disorders among the aging population. Additionally, it engages in partnerships with hospitals and healthcare providers, enhancing its distribution network and access to a broader customer base. The company may also explore opportunities in research collaborations and government contracts, contributing to its overall earnings.

Chaoju Eye Care Holdings Ltd. Financial Statement Overview

Summary
Chaoju Eye Care Holdings Ltd. is in a solid financial position with consistent revenue growth, strong profitability margins, a healthy balance sheet, and robust cash flow management. The company maintains low leverage and a strong equity base, which provides financial stability and potential for future growth. While net profit margins decreased slightly, the company continues to generate strong cash flows, indicating sustainable operations.
Income Statement
Chaoju Eye Care Holdings Ltd. shows steady revenue growth, with a noticeable increase from 2019 to 2024. The gross profit margin has been consistent around 43-44%, indicating strong operational efficiency. However, the net profit margin saw a slight decline from 16.7% in 2023 to 13.9% in 2024, suggesting potential cost pressures or increased expenses. EBIT and EBITDA margins remain healthy, reflecting good earnings before interest, taxes, depreciation, and amortization.
Balance Sheet
The company's balance sheet is strong, with a low debt-to-equity ratio of 0.094 in 2024, indicating low leverage and financial stability. The return on equity is solid, although it decreased slightly from 9.7% in 2023 to 8.4% in 2024, reflecting reduced net income. The equity ratio remains robust at approximately 80%, showing a strong capital structure.
Cash Flow
Chaoju Eye Care demonstrates strong cash flow management, with operating cash flow consistently exceeding net income. The free cash flow grew significantly by 23.9% from 2023 to 2024, indicating improved cash generation capabilities. The free cash flow to net income ratio is high, suggesting efficient cash conversion and strong liquidity.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.37B1.41B1.37B990.04M997.79M794.28M
Gross Profit573.00M611.30M621.13M434.70M448.67M349.48M
EBITDA316.81M335.37M434.82M267.87M304.65M225.18M
Net Income172.27M195.08M228.91M187.75M161.75M124.14M
Balance Sheet
Total Assets3.00B2.88B2.92B2.72B2.51B1.09B
Cash, Cash Equivalents and Short-Term Investments1.47B1.54B1.55B1.68B1.78B413.25M
Total Debt253.76M218.01M200.80M196.16M178.65M142.36M
Total Liabilities638.53M554.76M544.38M424.68M378.11M325.48M
Stockholders Equity2.35B2.32B2.36B2.27B2.11B737.25M
Cash Flow
Free Cash Flow279.75M354.36M286.02M148.29M189.18M196.16M
Operating Cash Flow361.45M354.36M372.57M273.41M249.39M248.75M
Investing Cash Flow-315.07M245.36M-654.10M-464.77M-578.51M-35.45M
Financing Cash Flow-160.85M-292.30M-204.01M-165.43M1.19B-39.61M

Chaoju Eye Care Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.71
Price Trends
50DMA
2.61
Positive
100DMA
2.68
Negative
200DMA
2.72
Negative
Market Momentum
MACD
0.01
Positive
RSI
47.19
Neutral
STOCH
18.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2219, the sentiment is Negative. The current price of 2.71 is above the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.61, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 18.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2219.

Chaoju Eye Care Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$601.91M7.295.33%9.14%0.47%50.46%
69
Neutral
HK$927.34M12.286.35%1.99%-1.61%-27.39%
68
Neutral
HK$1.87B9.877.31%9.29%-3.19%-20.30%
66
Neutral
HK$1.57B5.4220.47%4.37%-3.56%-17.45%
52
Neutral
HK$1.66B-11.56-4.66%0.49%-0.55%45.36%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
HK$2.01B-17.19-6.41%1.20%2.05%-285.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2219
Chaoju Eye Care Holdings Ltd.
2.65
0.16
6.43%
HK:1526
Rici Healthcare Holdings Ltd.
0.99
-0.24
-19.51%
HK:1846
EuroEyes International Eye Clinic Limited
2.90
-0.55
-15.94%
HK:3309
C-MER Eye Care Holdings Limited
1.63
-0.23
-12.37%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.80
-0.33
-15.49%
HK:3886
Town Health International Medical Group Ltd.
0.25
-0.03
-11.87%

Chaoju Eye Care Holdings Ltd. Corporate Events

Chaoju Eye Care Announces HK$50 Million Share Repurchase Plan
Nov 18, 2025

Chaoju Eye Care Holdings Ltd. has announced its intention to conduct an on-market share repurchase of up to HK$50 million, demonstrating confidence in its business outlook and aiming to create value for its shareholders. This move, subject to market conditions and regulatory compliance, reflects the company’s strategic decision to utilize its financial resources effectively while maintaining a solid financial position.

The most recent analyst rating on (HK:2219) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Chaoju Eye Care Holdings Ltd. stock, see the HK:2219 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 02, 2025